Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed Cimzia®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA). Those adult patients treated with Cimzia® that achieved early responses were found to have an increased chance of achieving longer-term outcomes.  

''These data show that when administered with methotrexate, certolizumab pegol offers rapid relief across a broad range of rheumatoid arthritis symptoms and that relatively few patients need to be treated before at least one patient reports clinical benefits from the positive relief the treatment provides,'' said lead investigator Dr. Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology and Rheumatology, at Stanford University, California. ''By assessing patient-reported outcomes at early-stages of treatment we are able to predict late-stage clinical outcomes and treatment benefits for patients, providing great reassurance to both patients and their healthcare professionals.''

PROs were secondary efficacy endpoints in RAPID 2 and were used to measure the impact of treatment with certolizumab pegol versus placebo. Number needed to treat (NNT) analysis was used in these post hoc analyses to interpret the PRO results. The NNT determines the number of patients that need to be treated in order to obtain the benefit of interest in one additional patient; therefore, small NNTs indicate favorable treatment effects. NNTs and minimum clinically important differences (MCIDs, which determine clinically meaningful improvements) were evaluated.

In the RAPID 2 study, patients with active RA (by 1987 American College of Rheumatology [ACR] classification criteria) with inadequate responses to MTX th
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... from a prominent international research and development foundation. ... promoting innovative research-based initiatives, including those addressing health ... for the delivery of naloxone that could widely ...
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
(Date:7/30/2014)... 2014 Nationally recognized leader in nursing ... since September 2013 has served as president of the ... dean of the College of Nursing at University of ... leadership of the NLN, as the nation's premier voice ... nursing and research institutions in the country. , ...
(Date:7/30/2014)... 2014 Within weeks freshman will begin to pour ... hopes this will be a time of growth and the start ... pause; it may not be as easy as it looks. Some ... switch their major at least once and many will switch two ... the costs are exacerbated when switching in the later years of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Throughout the ... patients with free oral cancer screenings. Using a new ... work to detect the disease in its early stages. ... tongue, cheek, mouth, sinuses, throat and other areas in ... Institute’s Surveillance, Epidemiology, and Ends Results (SEER) program, 30 ...
(Date:7/30/2014)... 2014 Serial entrepreneur, Paul Mata, spent the ... However, like most people, in 2008 he suffered extreme financial ... better way, Paul carefully studied the difference between people who ... not. Based on the knowledge he acquired, he was able ... life and health, but also grow his clients' personal and ...
(Date:7/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... are more likely to develop dementia, but researchers have been ... the two. Specifically, they haven,t been able to figure ... depression help bring on dementia, or does dementia cause people ... 30 in the journal Neurology sheds more light ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... ... is happy to provide his patients with Invisalign clear aligners, a new technology that ... make getting straight teeth easier than ever before. , ... Torrance, California (PRWEB) April 29, 2010 -- ...
... cancers could soon allow researchers to identify groups of ... with angiogenesis-inhibitor drugs, a Spanish team reports. Dr ... reports new findings from an analysis of 135 lung ... Carlos Camps, evaluated the expression of 8 different genes ...
... (found in some foods) may help alleviate the severity ... new research study appearing in the May 2010 print ... ( http://www.jleukbio.org ), differing intestinal bacteria in celiac patients ... manipulating the intestinal microbiota with dietary strategies such as ...
... ... FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments” , ... (Vocus) April 29, ... Letters—for Temperature, Humidity and other Controlled Environments” is now available from Veriteq ...
... risky but can be beneficial, researchers say , THURSDAY, ... better if they undergo deep brain stimulation surgery in ... One year after having the procedure, patients who underwent ... ability to get around and engage in routine daily ...
... ... saying that seems to ring true according to husbands whose wives have had plastic surgery. ... a look at the transformative journey from the husband,s perspective. , ... Newport Beach, Calif (Vocus) April 29, 2010 -- Dr. ...
Cached Medicine News:Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 2Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 3Health News:Spanish gene expression data promise targeting of anti-angiogenesis treatment 2Health News:Gut bacteria offer new insights -- and hope -- for people with celiac disease 2Health News:Guide for US FDA-Regulated Organizations Now Available 2Health News:Guide for US FDA-Regulated Organizations Now Available 3Health News:Adding Surgery to Meds May Improve Life With Parkinson's 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 3Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: